Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Hyperpolarized 13C MRI as a Biomarker of Aggressiveness & Response to Therapy in Patients With Advanced Solid Tumors

NCT05599048 is registered in ClinicalTrials.gov with Robert Bok, MD, PhD as lead sponsor.

NCT NCT05599048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05599048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Hyperpolarized 13C MRI as a Biomarker of Aggressiveness & Response to Therapy in Patients With Advanced Solid Tumors
Lead sponsor
Robert Bok, MD, PhD
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 15, 2022
Completion date
January 31, 2027
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor